Lite Strategy Inc. (LITS)
LITS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:InterestAndDividendIncomeOperating), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1262104/000119312526405328/0001193125-26-405328-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | LITS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2003 |
| SEC CIK | 0001262104 |
| SEC industry code | Finance Services |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $267K |
| Net income | -$71.2M |
| Operating income | -$66.6M |
| Net margin | -26647.9% |
| Operating margin | -24935.2% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $5.7M |
| Total assets | $42.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 95.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $4.3M cash; operating cash flow -$1.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 29,884,653 (2026-10-30); 36,785,397 a year earlier; 6,662,857 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-09-28 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Costa Mesa, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-12-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $142K, sold $946K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | Not filed | $16.0M | -$2.2M | $4.3M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2026 2026-06-30 | $53K | -$13.0M | -$1.2M | $5.7M | No debt tags | $267K | 10-K 2026-09-28 |
| Q3 2026 2026-03-31 | $54K | -$23.7M | -$1.5M | $7.5M | No debt tags | Needs four quarters | 10-Q 2026-05-13 |
| Q2 2026 2025-12-31 | $60K | -$30.8M | -$1.9M | $8.8M | No debt tags | Needs four quarters | 10-Q 2026-02-17 |
| Q1 2026 2025-09-30 | Not filed | -$3.6M | -$4.5M | $10.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-06-30 | $0 | -$2.7M | -$2.5M | $18.0M | No debt tags | $0 | 10-K 2025-09-26 |
| Q3 2025 2025-03-31 | $0 | -$2.6M | -$3.3M | $20.5M | No debt tags | $0 | 10-Q 2025-05-13 |
| Q2 2025 2024-12-31 | $0 | -$2.7M | -$3.7M | $23.7M | No debt tags | $0 | 10-Q 2025-02-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-09-28 |
| Latest annual report | 10-K | 2026-09-28 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-01-27 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -16.7% |
| 1 month | -29.8% |
| 3 months | -5.6% |
| Year to date | -35.6% |
| 1 year | -55.3% |
| From 52-week high | -57.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
| ACET | Adicet Bio Inc. | $2.75 | -1.08% | $25.7M |
| ABVC | ABVC BioPharma Inc. | $0.9400 | +3.30% | $25.4M |
| CRVO | CervoMed Inc. | $1.67 | -1.18% | $25.3M |
| IMMP | Immutep Limited | $3.40 | -2.30% | $25.1M |
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
| RMTI | Rockwell Medical Inc. | $6.76 | -4.38% | $26.9M |
| IXHL | Incannex Healthcare Inc. | $1.93 | -2.03% | $24.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier